PubMed
Humanin: a novel mitochondrial-derived peptide that protects against cellular stress
Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 52% · Mixed 30% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.025–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 92 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 49% · Mixed 42% · Unfavorable overall 9%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.025–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 29% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 190 repeat reporters
Published sources linked on the Humanin and KPV wiki pages.
PubMed
Hashimoto Y, Niikura T, Ito Y, et al. Proc Natl Acad Sci USA. 2003
PubMed
Mitchell AC, Jiang S, Peterhoff CM, et al. Mol Neurodegener. 2015
PubMed
Hazafa A, Batool A, Ahmad S, et al. Life sciences. 2021
PubMed
Rochette L, Meloux A, Zeller M, et al. Archives of cardiovascular diseases. 2020
PubMed
Luger TA, Brzoska T. Ann N Y Acad Sci. 2004
PubMed
Brzoska T, Luger TA, Maaser C, et al. Dig Dis Sci. 2010
PubMed
Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008
PubMed
Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Ichiyama T, Sato S, Okada K, et al. Annals of the New York Academy of Sciences. 2000